Kiniksa Pharmaceuticals Ltd (KNSA)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
KNSA
Kiniksa Pharmaceuticals Ltd
$45.84
+2.00%
HEALTHCARE · Cap: $3.44B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.29
+1.39%
HEALTHCARE · Cap: $56.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 658816% more annual revenue ($4.46T vs $677.56M). KNSA leads profitability with a 8.7% profit margin vs 2.5%. KNSA trades at a lower P/E of 59.9x. TAK earns a higher WallStSmart Score of 60/100 (C).
KNSA
Buy51
out of 100
Grade: C-
TAK
Buy60
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.1%
Fair Value
$35.10
Current Price
$45.84
$10.74 premium
Margin of Safety
-77.5%
Fair Value
$10.30
Current Price
$18.29
$7.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 65.0% year-over-year
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Generating 317.5B in free cash flow
Large-cap with strong market position
Areas to Watch
Premium valuation, high expectations priced in
4.2% revenue growth
3.3% earnings growth
ROE of 1.5% — below average capital efficiency
2.5% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : KNSA
The strongest argument for KNSA centers on Revenue Growth, Debt/Equity. Revenue growth of 65.0% demonstrates continued momentum.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. PEG of 0.39 suggests the stock is reasonably priced for its growth.
Bear Case : KNSA
The primary concerns for KNSA are P/E Ratio. A P/E of 59.9x leaves little room for execution misses.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, EPS Growth, Return on Equity. A P/E of 82.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
KNSA profiles as a hypergrowth stock while TAK is a value play — different risk/reward profiles.
TAK carries more volatility with a beta of 0.10 — expect wider price swings.
KNSA is growing revenue faster at 65.0% — sustainability is the question.
TAK generates stronger free cash flow (317.5B), providing more financial flexibility.
Bottom Line
TAK scores higher overall (60/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kiniksa Pharmaceuticals Ltd
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing transformative therapies to meet significant unmet medical needs. Its leading candidate, KPL-404, is a targeted monoclonal antibody designed to inhibit B and T lymphocyte activity, offering new therapeutic avenues for various autoimmune disorders. With a strong pipeline and a commitment to scientific excellence, Kiniksa is well-positioned for growth, supported by strategic collaborations and ongoing clinical trials. The company's efforts could potentially redefine treatment paradigms within the biopharmaceutical sector, making it an attractive investment opportunity for institutional investors.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?